Jazz Pharmaceuticals plc
JAZZ
Market Cap$6.03B
Close$
$249.48
142.4% upside
Current Fair Value
142.4% upsideUndervalued by 142.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.03 Billion |
|---|---|
| Enterprise Value | $3.76 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $9.06 |
| Beta | 0.38 |
| Outstanding Shares | 60,538,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 10.57 |
|---|---|
| PEG | 10.26 |
| Price to Sales | 1.54 |
| Price to Book Ratio | 1.54 |
| Enterprise Value to Revenue | 0.92 |
| Enterprise Value to EBIT | 5.17 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Jazz Pharmaceuticals plc
1,210 employeesJazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of...